Topiramate was initially approved by the United States Food and Drug Administration (FDA) in 1996. 

A 2005 study showed that topiramate effectively treats binge eating disorders and bulimia nervosa, leading to significant weight loss and improved glycemic control and blood pressure. Researchers found that topiramate lacks efficacy in acute mania, but its tolerability is high, with rare serious adverse events.

Topiramate treats patients aged 2 years and older as initial monotherapy for partial-onset or primary generalised tonic-clonic seizures. It also provides adjunctive therapy for adults and pediatric patients aged 2 to 16 with these types of seizures and for those 2 years and older with Lennox-Gastaut syndrome. Topiramate also helps in preventing migraine headaches in adults.

Consult your healthcare provider for proper administration of topiramate. The dosage depends on your specific condition and individual needs. You can take topiramate before, during, or after a meal. Never stop taking topiramate without discussing it with your healthcare provider, as sudden withdrawal may cause serious problems. If you have epilepsy, stopping abruptly can lead to seizures that do not stop. Your healthcare provider will instruct you on how to taper off topiramate safely.

Common Side Effects:

• Tingling or numbness
• Weight loss
• Loss of appetite
• Drowsiness
• Difficulty with memory
• Fatigue
• Confusion
• Dizziness

Rare Side Effects:

• Acute myopia
• Decreased sweating and hyperthermia
• Metabolic acidosis
• Cognitive/neuropsychiatric reactions
• Hyperammonemia and encephalopathy (with or without valproic acid)
• Kidney stones
• Hypothermia (with concomitant valproic acid)

Topiramate increases the risk of suicidal thoughts and behaviour, so closely monitor patients for any signs of these symptoms. It can harm unborn babies when administered to pregnant women, particularly increasing the risk of oral clefts in exposed infants. Be vigilant for hyperammonemia, especially when using topiramate in combination with valproic acid, as this can lead to encephalopathy. Additionally, ensure that patients stay hydrated to reduce the risk of kidney stones associated with the medication.

• Cognitive/Neuropsychiatric effects: Monitor for signs of cognitive dysfunction and psychiatric disturbances; consider dose adjustments or discontinuation if needed.
• Withdrawal of AEDs: Gradually withdraw antiepileptic drugs to minimise the risk of seizures.
• Renal and hepatic impairment: Adjust the dosage for patients with renal or hepatic impairment; exercise caution.
• Metabolic acidosis: Regularly monitor serum bicarbonate levels due to the risk of non-anion gap and hyperchloremic metabolic acidosis.
• Drug interactions: Assess for potential interactions with other medications.
• Pediatric use: Monitor pediatric patients closely. Although they may have a lower incidence of adverse reactions, vigilance is still essential.

Tell your doctor if you have a history of heart failure. Monitor your blood glucose levels regularly to prevent hypoglycemia while using linagliptin. Report any symptoms of low blood sugar without delay. Inform your doctor about all other medications you take to avoid potential interactions. Use linagliptin during pregnancy only when necessary. Watch for allergic reactions and report any issues right away.

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf
2. https://www.ema.europa.eu/en/medicines/human/referrals/topiramate
3. https://medlineplus.gov/druginfo/meds/a697012.html
4. https://www.ncbi.nlm.nih.gov/books/NBK554530/
5. Review of the use of Topiramate for treatment of psychiatric disorders | Annals of General Psychiatry | Full Text (biomedcentral.com)

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.